[1]尹仕红.抗肥胖药物疗效及安全性临床研究进展[J].国际内分泌代谢杂志,2017,37(03):168-171.[doi:10.3760/cma.j.issn.1673-4157.2017.03.006]
　Yin Shihong..Clinical study progression on efficacy and safety of anti-obesity drugs[J].International Journal of Endocrinology and Metabolism,2017,37(03):168-171.[doi:10.3760/cma.j.issn.1673-4157.2017.03.006]
点击复制

抗肥胖药物疗效及安全性临床研究进展()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年03期
页码:
168-171
栏目:
综述
出版日期:
2017-05-20

文章信息/Info

Title:
Clinical study progression on efficacy and safety of anti-obesity drugs
作者:
尹仕红
443000 宜昌,湖北三峡职业技术学院附属医院内科
Author(s):
Yin Shihong.
Department of Internal Medicine, Affiliated Hospital of Hubei Three Gorges Polytechnic College, Yichang 443000,China
关键词:
抗肥胖药物;  疗效;  安全性;  临床试验
Keywords:
Anti-obesity drug;  Efficacy;  Safety;  Clinical trial
DOI:
10.3760/cma.j.issn.1673-4157.2017.03.006
摘要:
抗肥胖药物治疗是肥胖管理中的辅助治疗手段。很多曾被广泛应用的抗肥胖药物因其不良反应而受到限制。近年来一些抗肥胖新药陆续上市,如奥利司他、利拉鲁肽、绿卡色林、芬特明/托吡酯、纳曲酮/安非他酮等。研究显示,有些降糖药物如二甲双胍、普兰林肽也具有减重作用。其他抗肥胖药物还包括植物提取物等。对抗肥胖药物的疗效及安全性的了解,将为临床治疗肥胖提供有力的证据。
Abstract:
The application of anti-obesity drugs is an adjunctive pharmacotherapy in the management of obesity. Many widely used anti-obesity drugs were limited for side effects. New anti-obesity drugs appear on the market continuously in recent years, such as orlistat,liraglutide, lorcaserin, fentermine/topiramate and naltrexone/bupropion. Some hypoglycemic drugs(such as metformin, pramlintide)also have effects of weight loss. Other anti-obesity drugs include plant extracts, etc. Understanding of the efficacy and safety of anti-obesity drugs will provide strong evidence for the clinical treatment of obesity.

参考文献/References:

[1] 王勇,范书英.2015年肥胖药物管理临床实践指南解读[J].中国全科医学,2016,19(5):497-499. DOI:10.3969/j.issn.1007-9572.2016.05.001.
[2] Sumithran P, Proietto J. Benefit-risk assessment of orlistat in the treatment of obesity[J].Drug Saf,2014,37(8):597-608. DOI: 10.1007/s40264-014-0210-7.
[3] Thomas EL, Makwana A, Newbould R,et al. Pragmatic study of orlistat 60 mg on abdominal obesity[J].Eur J Clin Nutr,2011,65(11):1256-1262. DOI: 10.1038/ejcn.2011.108.
[4] Astrup A, Carraro R, Finer N,et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide[J].Int J Obes(Lond),2012,36(6):843-854. DOI: 10.1038/ijo.2011.158.
[5] Davies MJ, Bergenstal R, Bode B,et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial[J].JAMA,2015,314(7):687-699. DOI: 10.1001/jama.2015.9676.
[6] Aronne L, Shanahan W, Fain R,et al. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials[J].Postgrad Med,2014,126(6):7-18. DOI: 10.3810/pgm.2014.10.2817.
[7] Allison DB, Gadde KM, Garvey WT,et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial(EQUIP)[J].Obesity(Silver Spring),2012,20(2):330-342. DOI: 10.1038/oby.2011.330.
[8] Garvey WT, Ryan DH, Bohannon NJ,et al. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release[J].Diabetes Care,2014,37(12):3309-3316. DOI: 10.2337/dc14-0930.
[9] Siebenhofer A, Jeitler K, Horvath K, et al. Long-term effects of weight-reducing drugs in people with hypertension[J]. Cochrane Database Syst Rev, 2016,3:CD007654. DOI: 10.1002/14651858.CD007654.pub4.
[10] Makowski CT, Gwinn KM, Hurren KM. Naltrexone/bupropion: an investigational combination for weight loss and maintenance[J].Obes Facts,2011,4(6):489-494. DOI:10.1159/000335352.
[11] Kolotkin RL, Chen S, Klassen P, et al. Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity[J].Clin Obes,2015,5(5):237-244. DOI: 10.1111/cob.12108.
[12] Nissen SE, Wolski KE, Prcela L,et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial[J].JAMA,2016,315(10):990-1004. DOI: 10.1001/jama.2016.1558.
[13] Soto-Molina H, Pizarro-Castellanos M, Rosado-Pérez J,et al. Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial[J].Int J Clin Pharmacol Ther,2015,53(7):541-549. DOI: 10.5414/CP202135.
[14] 中华医学会内分泌学会肥胖学组.中国成人肥胖症防治专家共识[J].中华内分泌代谢杂志,2011,27(9):711-717. DOI:10.3760/cma.j.issn.1000-6699.2011.09.003.
[15] Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study[J].Diabetes Care,2012,35(4):731-737. DOI: 10.2337/dc11-1299.
[16] Herrmann K, Frias JP, Edelman SV,et al. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy[J].Postgrad Med,2013,125(3):136-144. DOI: 10.3810/pgm.2013.05.2635.
[17] Lawson EA, Marengi DA, DeSanti RL,et al. Oxytocin reduces caloric intake in men[J].Obesity(Silver Spring),2015,23(5):950-956.DOI: 10.1002/oby.21069.
[18] Li L, Liu QS, Liu WH,et al. Treatment of obesity by endoscopic gastric intramural injection of botulinum toxin A: a randomized clinical trial[J].Hepatogastroenterology,2012,59(118):2003-2007. DOI: 10.5754/hge11755.
[19] Astell KJ, Mathai ML, Su XQ. A review on botanical species and chemical compounds with appetite suppressing properties for body weight control[J].Plant Foods Hum Nutr,2013,68(3):213-221. DOI: 10.1007/s11130-013-0361-1.
[20] Park SH, Huh TL, Kim SY,et al. Antiobesity effect of Gynostemma pentaphyllum extract(actiponin): a randomized, double-blind, placebo-controlled trial[J].Obesity(Silver Spring),2014,22(1):63-71. DOI: 10.1002/oby.20539.
[21] Hu Y, Ehli EA, Kittelsrud J,et al. Lipid-lowering effect of berberine in human subjects and rats[J].Phytomedicine,2012,19(10):861-867. DOI: 10.1016/j.phymed.2012.05.009.

相似文献/References:

[1]李冬梅.高压氧治疗糖尿病足的疗效研究[J].国际内分泌代谢杂志,2014,(05):356.[doi:10.3760/cma.j.issn.1673-4157.2014.05.020]
　Li Dongmei..Therapeutic effects of hyperbaric oxygen on patients with diabetic foot[J].International Journal of Endocrinology and Metabolism,2014,(03):356.[doi:10.3760/cma.j.issn.1673-4157.2014.05.020]
[2]周华梅,吴晓颖,张毅.十二指肠黏膜表面重建术治疗2型糖尿病的研究进展[J].国际内分泌代谢杂志,2022,42(02):146.[doi:10.3760/cma.j.cn121383-20201123-11049]
　Zhou Huamei,Wu Xiaoying,Zhang Yi..Treatment of duodenal mucosal surface reconstruction in type 2 diabetes mellitus patients[J].International Journal of Endocrinology and Metabolism,2022,42(03):146.[doi:10.3760/cma.j.cn121383-20201123-11049]

备注/Memo

备注/Memo:
通信作者: 尹仕红,Email: yinsh65@163.com
更新日期/Last Update: 2017-05-20